Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Norfolk, Virginia 23507


Purpose:

S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein. It is currently being evaluated for future licensing. This study aims to demonstrate the safety and immunogenicity of a single dose of StaphVAX in patients who are candidates for knee or hip arthroplasty.


Criteria:

Inclusion Criteria: - age 18 years or older - candidate for knee or hip replacement - expectation of protocol compliance - negative pregnancy test, where appropriate Exclusion Criteria: - known S. aureus infection in the prior 3 months - infection in the prior 2 weeks - Known HIV infection - immunomodulatory drugs - Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer) - Hypersensitivity to components of StaphVAX


NCT ID:

NCT00211926


Primary Contact:

Study Director
Preston Holley, MD
Nabi Biopharmaceuticals


Backup Contact:

N/A


Location Contact:

Norfolk, Virginia 23507
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.